Samsung Bioepis Confirms Quality-of-Life Gains, Safety of Adalimumab Biosimilar Adaloce
Seoul Economic Daily
Last updated: May 18, 2026
Samsung Bioepis presented real-world patient prescription data for Adaloce, a biosimilar to AbbVie's Humira (adalimumab), at a domestic academic conference. This data provides insights into the drug's usage patterns and effectiveness in clinical practice within South Korea.
- The presented data focused on the prescription trends of Adaloce, Samsung Bioepis' biosimilar of adalimumab, a widely used treatment for autoimmune diseases.
- The company shared specific patient prescription data, indicating the real-world application and adoption of Adaloce among Korean healthcare providers.
- This disclosure at an academic conference suggests a move towards greater transparency regarding the performance and utilization of biosimilar drugs in the South Korean market.
- The data aims to demonstrate Adaloce's efficacy and safety profile as observed in actual patient care settings, potentially influencing physician prescribing habits and patient access.
- The presentation highlights Samsung Bioepis' commitment to providing evidence-based information supporting the value of its biosimilar offerings.
- This initiative contributes to the broader understanding of biosimilar market dynamics and their integration into standard medical treatment protocols for autoimmune conditions.
